FONT-SIZE Plus   Neg

Amgen Blood Cancer Drug Meets Primary Endpoint In Late-Stage Study

Amgen Inc. (AMGN) Monday said its blood cancer drug Kyprolis in combination with two other drugs helped patients live significantly longer compared to standard treatment.

The California-based drug giant said patients with relapsed multiple myeloma when treated with Kyprolis in combination with Revlimid and low-dose dexamethasone lived 8.7 months longer without disease worsening compared to patients treated with only Revlimid and low-dose dexamethasone.

Multiple myeloma is the second most common hematologic cancer that results from an abnormality of plasma cells, usually in the bone marrow. In the US, about 70,000 people are living with multiple myeloma and around 24,000 new cases are diagnosed annually.

The FDA had granted accelerated approval of Kyprolis for the treatment of patients with multiple myeloma in 2012. Kyprolis is marketed in the US by Amgen's subsidiary Onyx Pharmaceuticals Inc.

The study called Aspire was conducted on 792 patients. Amgen said patients treated with Kyprolis lived for a median of 26.3 months without disease worsening, a significant improvement compared to the 17.6 months in patients who received standard treatment.

Chief Executive Robert Bradway said "Our mission at Amgen is to serve patients by advancing medicines that address serious disease. Kyprolis is an important building block in our robust, differentiated pipeline."

AMGN is currently trading at $126.84, up $1.29 or 1.03%, on the Nasdaq.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Bond management titan Bill Gross has filed suit against his former employer, PIMCO, for breach of contract related to his ouster from the company. Gross is looking for damages of at least $200 million for forcing him out of the company, according to court filings. Gross claims that other managers conspired to push him out of the firm he co-founded in order to improve their own finances. Large U.S. companies are holding trillions of dollars overseas in an effort to avoid U.S. taxes, with big-name firms like Apple (AAPL), Pfizer (PFE) and PepsiCo (PEP) named as notable examples. This is the claim made by a pair of non-profit groups, who released a study based on the firms' financial statements. Alcoa Inc. (AA), the largest producer of aluminum in the US, Thursday reported a sharp decline in profit for the third quarter, as sales dropped 11 percent reflecting divestitures and currency headwinds. Both the earnings and revenues fell short of Wall Street analysts' estimates, sending its shares...
comments powered by Disqus
Follow RTT